Evaluation of combination therapies with colistin in an experimental mouse pneumonia model induced by carbapenem‐resistant Acinetobacter baumannii strain
Fundamental & Clinical Pharmacology · 2023
DOI: 10.1111/fcp.12891 ↗Kurz gefasst
Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, 2023. Verfasst von Onur Unal und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Suleyman Demirel University, Isparta, Turkey. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Acinetobacter Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Scientific Research Fund of Suleyman Demirel University.
Abstract (Originalsprache)
The treatment options are limited in Acinetobacter baumannii infections. In this study, the effectiveness of colistin monotherapy and combinations of colistin with different antibiotics were investigated in an experimental pneumonia model induced by carbapenem‐resistant A. baumannii strain. Mice in the study were divided into five groups as control (no treatment), colistin monotherapy, colistin + sulbactam, colistin + imipenem, and colistin + tigecycline combinations. The modified experimental surgical pneumonia model of Esposito and Pennington was applied to all groups. The presence of bacteria in blood and lung samples was investigated. Results were compared. In blood cultures, while there was no difference between the control and colistin groups, there was a statistical difference between the control and the combination groups ( P = 0.029). When the groups were compared in terms of lung tissue culture positivity, there was a statistical difference between the control group and all treatment groups (colistin, colistin + sulbactam, colistin + imipenem, and colistin + tigecycline) ( P = 0.026, P < 0.001, P < 0.001, and P = 0.002, respectively). The number of microorganisms that grew in the lung tissue was found to be statistically significantly lower in all treatment groups in comparison with the control group ( P = 0.001). Both monotherapy and combination therapies of colistin were found to be effective in the treatment of carbapenem‐resistant A. baumannii pneumonia, but the superiority of combination therapies over colistin monotherapy has not been demonstrated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Suleyman Demirel University, Isparta, Turkey.
- Laboratory of Medical Microbiology, Isparta City Hospital, Isparta, Turkey.
- Faculty of Medicine, Department of Medical Microbiology, Suleyman Demirel University, Isparta, Turkey.
- Department of Infectious Diseases and Clinical Microbiology, Istanbul Aydin University, Istanbul, Turkey.
ORCID-Profile: Onur Unal, Fusun Zeynep Akcam
Förderung
- Scientific Research Fund of Suleyman Demirel University
Zitieren
APA
Unal, O., Kaya, O., Ozturk, T., Cetin, E. S., Gonen, I., Temel, E. N., & Akcam, F. Z. (2023). Evaluation of combination therapies with colistin in an experimental mouse pneumonia model induced by carbapenem‐resistant Acinetobacter baumannii strain. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.12891
Vancouver
Unal O, Kaya O, Ozturk T, Cetin ES, Gonen I, Temel EN, et al. Evaluation of combination therapies with colistin in an experimental mouse pneumonia model induced by carbapenem‐resistant Acinetobacter baumannii strain. Fundamental & Clinical Pharmacology. 2023. doi:10.1111/fcp.12891
BibTeX
@article{Unal2023,
author = {Unal, Onur and Kaya, Onur and Ozturk, Tuba and Cetin, Emel Sesli and Gonen, Ibak and Temel, Esra Nurlu and Akcam, Fusun Zeynep},
title = {Evaluation of combination therapies with colistin in an experimental mouse pneumonia model induced by carbapenem‐resistant Acinetobacter baumannii strain},
journal = {Fundamental & Clinical Pharmacology},
year = {2023},
doi = {10.1111/fcp.12891}
}
EUVIMED